Polyplus Introduces Off-the-Shelf Plasmids for AAV2 Production: Plans to Expand Plasmid Portfolio to Support Full Range of AAV Serotypes in 2024
LY-M001 injection, a gene therapy drug for Gaucher disease by Lingyi Biotech received FDA approval for clinical trials
Polyplus Expands GMP Offer with Protein Production and Adds GMP Capacity in Belgium
Polyplus and MarkHerz Partner to Advance Cell and Gene Therapy Process Standards and Lower Costs.
Polyplus Expands LipidBrick® Library to Optimize LNP Formulation for mRNA Therapeutics
Polyplus Launches FectoVIR®-LV Transfection Reagent with New DOE Service Options
Polyplus Introduces LipidBrick® for LNP Formulation in mRNA Therapeutics